Jazz Pharmaceuticals PLC
JAZZ115.280USD
-0.240-0.21%
Market hours （ET）Quotes delayed by 15 min
7.10BMarket Cap
14.73P/E TTM
More Details of Jazz Pharmaceuticals PLC Company
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Company Info
Ticker SymbolJAZZ
Company nameJazz Pharmaceuticals PLC
IPO dateJan 18, 2012
CEOMs. Renee D. Gala
Number of employees2800
Security typeOrdinary Share
Fiscal year-endJan 18
AddressFifth Floor, Waterloo Exchange
CityDUBLIN
Stock exchangeNASDAQ Global Select Consolidated
CountryIreland
Postal code- -
Phone35316347800
Websitehttps://www.jazzpharma.com/
Ticker SymbolJAZZ
IPO dateJan 18, 2012
CEOMs. Renee D. Gala
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.27M
+8.67%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
335.96K
-0.30%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
31.28K
--
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
29.39K
--
Mr. Kenneth W. (Ken) O'Keefe
Mr. Kenneth W. (Ken) O'Keefe
Independent Director
Independent Director
27.68K
--
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
21.63K
-15.90%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
12.22K
--
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
11.07K
--
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Lead Independent Director
Lead Independent Director
8.96K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.27M
+8.67%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
335.96K
-0.30%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
31.28K
--
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
29.39K
--
Mr. Kenneth W. (Ken) O'Keefe
Mr. Kenneth W. (Ken) O'Keefe
Independent Director
Independent Director
27.68K
--
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
21.63K
-15.90%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Xywav
344.80M
38.40%
Epidiolex/epidyolex
217.74M
24.25%
Rylaze
94.23M
10.50%
Zepzelca
63.03M
7.02%
High-sodium oxybate AG royalty revenue
48.95M
5.45%
Other
129.09M
14.38%
By RegionUSD
Name
Revenue
Proportion
United States
797.95M
88.87%
Europe
83.61M
9.31%
All Others
16.29M
1.81%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Xywav
344.80M
38.40%
Epidiolex/epidyolex
217.74M
24.25%
Rylaze
94.23M
10.50%
Zepzelca
63.03M
7.02%
High-sodium oxybate AG royalty revenue
48.95M
5.45%
Other
129.09M
14.38%
Shareholding Stats
Updated: Tue, Jul 22
Updated: Tue, Jul 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.91%
BlackRock Institutional Trust Company, N.A.
8.61%
LSV Asset Management
4.08%
Dimensional Fund Advisors, L.P.
3.85%
State Street Global Advisors (US)
3.25%
Other
70.31%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.91%
BlackRock Institutional Trust Company, N.A.
8.61%
LSV Asset Management
4.08%
Dimensional Fund Advisors, L.P.
3.85%
State Street Global Advisors (US)
3.25%
Other
70.31%
Shareholder Types
Shareholders
Proportion
Investment Advisor
53.78%
Investment Advisor/Hedge Fund
31.14%
Hedge Fund
9.59%
Research Firm
3.30%
Individual Investor
3.06%
Pension Fund
2.14%
Bank and Trust
1.04%
Venture Capital
0.85%
Sovereign Wealth Fund
0.18%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1196
63.65M
105.18%
-6.19M
2025Q1
1235
63.66M
105.15%
-6.35M
2024Q4
1202
62.66M
103.17%
-6.51M
2024Q3
1172
61.48M
99.60%
-6.16M
2024Q2
1167
61.28M
97.21%
-6.97M
2024Q1
1163
63.08M
101.15%
-2.43M
2023Q4
1156
61.76M
98.11%
-3.48M
2023Q3
1158
61.08M
96.76%
-4.05M
2023Q2
1197
61.00M
95.34%
-4.11M
2023Q1
1207
61.36M
96.91%
-3.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
5.99M
9.91%
-18.47K
-0.31%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.21M
8.61%
-33.38K
-0.64%
Mar 31, 2025
LSV Asset Management
2.47M
4.08%
-64.88K
-2.56%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.33M
3.85%
+293.36K
+14.42%
Mar 31, 2025
State Street Global Advisors (US)
1.97M
3.25%
-2.23K
-0.11%
Mar 31, 2025
Capital World Investors
1.93M
3.19%
+4.45K
+0.23%
Mar 31, 2025
EcoR1 Capital, LLC
1.71M
2.82%
--
--
Mar 31, 2025
JP Morgan Asset Management
1.50M
2.48%
+71.69K
+5.01%
Mar 31, 2025
Columbia Threadneedle Investments (US)
1.35M
2.24%
-136.12K
-9.14%
Mar 31, 2025
Fuller & Thaler Asset Management Inc.
1.33M
2.2%
+391.66K
+41.69%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
AdvisorShares Pure Cannabis ETF
5.57%
Cambria Cannabis ETF
4.57%
SPDR S&P Pharmaceuticals ETF
3.68%
iShares U.S. Pharmaceuticals ETF
3.29%
First Trust NASDAQ Pharmaceuticals ETF
2.98%
Invesco Pharmaceuticals ETF
2.62%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.61%
First Trust Health Care Alphadex Fund
1.87%
Tema Neuroscience and Mental Health ETF
1.86%
VictoryShares Small Cap Free Cash Flow ETF
1.71%
View more
AdvisorShares Pure Cannabis ETF
Proportion5.57%
Cambria Cannabis ETF
Proportion4.57%
SPDR S&P Pharmaceuticals ETF
Proportion3.68%
iShares U.S. Pharmaceuticals ETF
Proportion3.29%
First Trust NASDAQ Pharmaceuticals ETF
Proportion2.98%
Invesco Pharmaceuticals ETF
Proportion2.62%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.61%
First Trust Health Care Alphadex Fund
Proportion1.87%
Tema Neuroscience and Mental Health ETF
Proportion1.86%
VictoryShares Small Cap Free Cash Flow ETF
Proportion1.71%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
